Estrogen and ERalpha: culprits in cervical cancer?

Trends Endocrinol Metab. 2010 Aug;21(8):504-11. doi: 10.1016/j.tem.2010.03.005. Epub 2010 Apr 22.

Abstract

Estrogen and its receptors are implicated in the promotion and prevention of various cancers. Although the uterine cervix is highly responsive to estrogen, the role of estrogen in cervical cancer, which is strongly associated with human papillomavirus (HPV) infections, is poorly understood. Recent studies in HPV transgenic mouse models provide evidence that estrogen and its nuclear receptor promote cervical cancer in combination with HPV oncogenes. Although epidemiological studies further support this hypothesis, there is little experimental data assessing the hormonal responsiveness of human cervical cancers. If these cancers are dependent on estrogen, then drugs targeting estrogen and its receptors could be effective in treating and/or preventing cervical cancer, the second leading cause of death by cancer among women worldwide.

Publication types

  • Review

MeSH terms

  • Alphapapillomavirus / drug effects
  • Alphapapillomavirus / genetics
  • Animals
  • Estrogen Antagonists / pharmacology*
  • Estrogen Antagonists / therapeutic use
  • Estrogen Receptor alpha / antagonists & inhibitors*
  • Estrogen Receptor alpha / physiology*
  • Estrogens / physiology*
  • Female
  • Genes, Viral
  • Humans
  • Oncogenes
  • Papillomavirus Infections / physiopathology
  • Risk Factors
  • Selective Estrogen Receptor Modulators / pharmacology
  • Selective Estrogen Receptor Modulators / therapeutic use
  • Uterine Cervical Neoplasms / drug therapy*
  • Uterine Cervical Neoplasms / epidemiology
  • Uterine Cervical Neoplasms / physiopathology*
  • Uterine Cervical Neoplasms / prevention & control

Substances

  • Estrogen Antagonists
  • Estrogen Receptor alpha
  • Estrogens
  • Selective Estrogen Receptor Modulators